RxDoctor Payments Data

Michael Nestasie, DO

Cardiovascular Disease · Natrona Heights, PANPI 1952764375

Payments from drug & device makers

$8,157in general payments, 2019–2025

Across 193 payments — averaging $42.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$2K
  • Edwards Lifesciences$1K
  • Abbott$1K
  • Medtronic$867
  • Boston Scientific$612
  • Amgen$336
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$1,58419%
  • Food & beverage$5,94973%
  • Education$6248%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,157 in reported general payments places this provider in the 75th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$34,339
Medicare patients
215
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$36,768
JardianceEmpagliflozin19$16,075
Ranolazine ErRanolazine16$824
Metoprolol Succinate48$592
Rosuvastatin Calcium39$500
Valsartan15$404
Bumetanide15$338
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$257
Isosorbide Mononitrate ErIsosorbide Mononitrate14$253
Atorvastatin Calcium23$241
Amlodipine Besylate51$221
Pantoprazole Sodium12$122
Spironolactone18$105
Furosemide20$36
Lisinopril12$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$179$36,76839 claims
Boehringer IngelheimJardiance$114$16,07519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Natrona Heights

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →